Join

Compare · AXDX vs BIO

AXDX vs BIO

Side-by-side comparison of Accelerate Diagnostics Inc. (AXDX) and Bio-Rad Laboratories Inc. (BIO): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both AXDX and BIO operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
  • BIO is the larger of the two at $17.74B, about 90.0x AXDX ($197.2M).
  • BIO has hit the wire 2 times in the past 4 weeks while AXDX has been quiet.
  • BIO has more recent analyst coverage (11 ratings vs 1 for AXDX).
MetricAXDXBIO
Company
Accelerate Diagnostics Inc.
Bio-Rad Laboratories Inc.
Price
$0.14+59.82%
$287.83+2.31%
Market cap
$197.2M
$17.74B
1M return
-
+5.20%
1Y return
-
+20.00%
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Laboratory Analytical Instruments
Exchange
NASDAQ
NYSE
IPO
1980
News (4w)
0
2
Recent ratings
1
11
AXDX

Accelerate Diagnostics Inc.

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was founded in 1982 and is headquartered in Tucson, Arizona.

BIO

Bio-Rad Laboratories Inc.

Bio-Rad Laboratories, Inc. develops, manufactures, and markets life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

Latest AXDX

Latest BIO